InVivo Molecular Ultrasound Assessment of Glioblastoma Neovasculature with Endoglin-Targeted Microbubbles

Figure 8

The in vivo assessment of the CD105 expression levels in the subcutaneous glioblastoma xenograft tumors (small, medium, and large sizes). (a) The dual-mode US imaging (B-mode and contrast mode) of tumors by using the CD105-targeted MBs, scale bar = 1 mm; (b) the ex vivo immunohistochemistry (IHC) test (e.g., CD105 and CD31) of the tumor tissues. CD105 was confirmed to be expressed on the endothelial cells; (c) the differential targeted enhancement (dTE) measured in the small, medium, and large glioblastoma tumor groups by using the CD105-targeted MBs and nontargeted MBs; (d) the qualification of the expression levels of CD105 and CD31 in tumor tissues assessed by ex vivo immunohistochemistry (IHC). The statistical results indicated that the expression levels of endoglin (CD105) in the small and medium size tumors were significantly higher () in comparison with CD31. And in large size tumors, the expression levels of endoglin (CD105) were significantly lower () than those of CD31.

(a)

(b)

(c)

(d)